These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19384691)

  • 21. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular therapy of pancreatic cancer.
    Plentz RR; Manns MP; Greten TF
    Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
    Cardin DB; Goff L; Li CI; Shyr Y; Winkler C; DeVore R; Schlabach L; Holloway M; McClanahan P; Meyer K; Grigorieva J; Berlin J; Chan E
    Cancer Med; 2014 Jun; 3(3):572-9. PubMed ID: 24574334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trials: time for a new era in clinical trial design.
    Mandrekar SJ; Sargent DJ
    J Thorac Oncol; 2010 Jul; 5(7):932-4. PubMed ID: 20581575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib: in hepatocellular carcinoma.
    Simpson D; Keating GM
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design issues of randomized phase II trials and a proposal for phase II screening trials.
    Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
    J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib in lung cancer: clinical developments and future directions.
    Blumenschein G
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
    Chen CM; Chi Y; Chang HM
    J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.